| Literature DB >> 31572493 |
Dingyu Liu1, Can Huang1, Jiaxin Guo1, Peiji Zhang1, Tao Chen1, Zhiwen Wang1, Xueming Zhao1.
Abstract
BACKGROUND: Metabolic engineering has expanded from a focus on designs requiring a small number of genetic modifications to increasingly complex designs driven by advances in multiplex genome editing technologies. However, simultaneously modulating multiple genes on the chromosome remains challenging in Bacillus subtilis. Thus, developing an efficient and convenient method for B. subtilis multiplex genome editing is imperative.Entities:
Keywords: CRISPR/Cas9n; Combinatorial metabolic engineering; Multiplex genome editing; Nick repair mechanism; Riboflavin
Year: 2019 PMID: 31572493 PMCID: PMC6764132 DOI: 10.1186/s13068-019-1537-1
Source DB: PubMed Journal: Biotechnol Biofuels ISSN: 1754-6834 Impact factor: 6.040
Fig. 1Transformation efficiency of different plasmids for CRISPR-Cas9/Cas9n-mediated gene editing. The target gene of the gRNA was the amyE locus. The error bars represent t standard deviations from three repeated experiments
Fig. 2The CRISPR/Cas-mediated system for iterative genome editing. a The components and procedure of the CRISPR/Cas based system. Two plasmids respectively harboring gRNA and donor DNA are introduced into the cells, after which expression of Cas protein and homologous recombination are implemented. Gene modifications were introduced, allowing the cells to escape CRISPR mediated cleavage by abolishing the protospacer or the PAM sequences. When induced by mannose, gRNA targeting the rep60 gene is expressed to eliminate the donor DNA plasmid. The gRNA plasmid was eliminated by inhibiting the replication of its thermo-sensitive replicon at increased temperature. b Step by step diagram of the iterative genome editing procedure. The time required for each step is shown in red
Fig. 3Characterization of CRISPR-Cas9/Cas9n mediated genome editing. a Editing efficiency and CFU for sequence deletions using CRISPR/Cas9 or CRISPR/Cas9n. For deletion, the region of the amyE gene and flanking sequences were deleted. b Editing efficiency and CFU for gene insertions. A deleted sequence in the amyE region was restored. c Editing efficiency and CFU for large genomic deletions. A prophage (-like) regions was deleted. In these genetic modifications, 500 bp homologous-arms were used for recombination. All error bars represent the value of standard deviation which were calculated from three repeated experiments
Fig. 4Strategy for CRISPR-Cas9/Cas9n mediated multiplex point mutations. a Assumed mechanism of CRISPR-Cas9/Cas9n mediated multiplex breaks. b Editing efficiency and CFU for multiplex point mutations using the CRISPR-Cas9/Cas9n system. In these genetic modifications, 500 bp homologous-arms were used to achieve recombination. All error bars represent the value of standard deviation which were caculated from three repeated experiments
Fig. 5Mechanism of ligD mediated nick ligation in B. subtilis. a The ligD-mediated nick re-ligation. A Ku homodimer binds to the end of the DNA break and recruits LigD protein. The polymerase domain of LigD specifically binds to a 5′-phosphate (P) and promotes end-synapsis-, together with protein Ku. The nuclease and polymerase activities of LigD, and possibly other factors, process the break termini, if required, to restore complementary ends. Finally, ligation of the nick by LigD repairs the break. b Predominantly HDR repair in ΔligD. When LigD is repressed, the DNA break is repaired by the HDR mechanism
Fig. 6Strategy for improving CRISPR-Cas9/Cas9n mediated gene editing by regulating ligD. a Cell growths of strains with CRISPR-Cas9/Cas9n mediated gene editing under different induction conditions. Promoter P43 was used to overexpress ligD. The amyE was targeted for Cas9/Cas9n-induced genome cleavage in this study. b Editing efficiency for multiplex point mutations by the improved CRISPR-Cas9/Cas9n system. In these genetic modifications, 500 bp homologous-arms were used to achieve recombination. All error bars represent the value of standard deviation which were caculated from three repeated experiments
Fig. 7Optimization of the riboflavin operon by improved CRISPR/Cas9n mediated multiplex gene editing. a Integration of the riboflavin synthesis pathway genes and regulatory elements. b Production of riboflavin in 96-well plates. The red bar shows the control strain. c Yield of riboflavin in 96-well plates. Striped bar show strains that were selected for secondary screening due to high yields, which were not among the 20 highest-producing strains. The data show the average values and standard deviations of triplicate experiments
Fig. 8Productions and yields of riboflavin in shake-flask fermentation. The strains were cultivated aerobically in 50 mL of YE medium in 500 mL shake-flask at 240 rpm and 41 °C with an initial inoculum of 2% (v/v). Striped bar indicate strains for which the 5′-UTR regions of the mRNA secondary structure of riboflavin operon genes were simulated. The data are the average values and standard deviations from triplicate experiments
Sequences in RBS regions of the riboflavin operon genes of the 20 optimized strains
| Strain | RBS region of | RBS region of | RBS region of |
|---|---|---|---|
| CY23 | ATATAAG | GTAAGAA | AAGAAGG |
| CY41 | ATTAGAG | AAGGGGA | AGTGAGA |
| CY45 |
| AGGTGGA |
|
| CY43 | AGACAGG | GGCTGGA | AGATGAG |
| CY47 | AACATAG |
| ATAGAGA |
| CY124 | AATGAGA | ACAAGGA | AGGATGG |
| CY79 | AGTAAGA | AAAGGAG | GTAGGAA |
| CY6 |
| ---GAGGb | AGTAGAA |
| CY107 | GGAGAGG | ATTGGAG | AAGAGGA |
| CY49 | ATTGAGG | AGTCGAA | GTAAAAG |
| CY11 | AGTCGAA |
| ---GGAG |
| CY44 | GGGAGAA | ATGTGAA | GGCTAGG |
| CY14 | GGAGTAG | GATGGAA | AGTTGAG |
| CY46 | AGTTGAG | AAAGAGA | AAGATAA |
| CY16 | AATGGAG | AATGGAG | AGTTGAG |
| CY18 | GCGAAGG | AGCGAGG | ATGGGAG |
| CY33 | AGGGAGA | AATGGAG | GCGAAGG |
| CY24 | GTTGAAG | AGGAGAA | AAGAAAG |
| CY17 | AAAGAGG | ATTGGAG | AGCAGGA |
| CY15 | AGGAGGA |
| AATGGAG |
aThe Wild type RBSs are shown in bold
b“-” indicates base deletion in this location
Strains and plasmids used in this study
| Name | Relevant genotype | Source/reference |
|---|---|---|
| Strains | ||
| | Wild-type strain, | BGSCa |
| | This study | |
| BS89 | [ | |
| BS89Δ | BS89Δ | This study |
| CY series strains | Modulation library strains generated with CRISPR/Cas9n technique | This study |
| | F−, φ80 | Lab stock |
| Plasmids | ||
| pCas9cur | Lab stock | |
| pBSCas9 | P | This study |
| pBSCas9n | pBSCas9 harboring Cas9 mutation | This study |
| pDonor | AmpR, P | This study |
| pHG | Derived from pUC18 for multiple gRNA construction | This study |
| pUC18 | Lab stock | |
| pEBs- | Lab stock | |
| pAX01 | Lab stock | |
| pHP13 | Lab stock | |
| pBSCas9- | Derived from pBSCas9 for targeting | This study |
| pBSCas9n- | Derived from pBSCas9n for targeting | This study |
| pBSCas9-Ins1 kb | Derived from pBSCas9 for targeting Δ1kb | This study |
| pBSCas9n-Ins1kb | Derived from pBSCas9n for targeting Δ1kb | This study |
| pBSCas9-Ins2kb | Derived from pBSCas9 for targeting Δ2kb | This study |
| pBSCas9n-Ins2kb | Derived from pBSCas9n for targeting Δ2kb | This study |
| pBSCas9- | Derived from pBSCas9 for targeting | This study |
| pBSCas9n- | Derived from pBSCas9n for targeting | This study |
| pBSCas9- | Derived from pBSCas9 for targeting | This study |
| pBSCas9n- | Derived from pBSCas9n for targeting | This study |
| pBSCas9-LGgRNA | Derived from pBSCas9 for targeting large DNA fragment | This study |
| pBSCas9n-LGgRNA | Derived from pBSCas9n for targeting large DNA fragment | This study |
| pDonor-Del1kb | Derived from pDonor for 1 kb deletion | This study |
| pDonor-Del2kb | Derived from pDonor for 2 kb deletion | This study |
| pDonor-Del4kb | Derived from pDonor for 4 kb deletion | This study |
| pDonor-Del6kb | Derived from pDonor for 6 kb deletion | This study |
| pDonor-Del8kb | Derived from pDonor for 8 kb deletion | This study |
| pDonor-Ine1kb | Derived from pDonor for 1 kb insertion | This study |
| pDonor-Ine2kb | Derived from pDonor for 2 kb insertion | This study |
| pDonor-DelLDNA | Derived from pDonor for large DNA fragment deletion | This study |
| pDonor-Mu | Derived from pDonor for codon replacement in | This study |
| pDonor-Mu | Derived from pDonor for codon replacement in | This study |
| pDonor-Mu | Derived from pDonor for codon replacement in | This study |
| pBSCas9n-gRNArib | Derived from pBSCas9n for targeting | This study |
| pDonor-ribRBSLib | Derived from pDonor for generating a combinatorial library | This study |
Cm chloramphenicol; Amp ampicillin; Em erythromycin; R resistance
aBacillus Genetic Stock Center